Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110] Draft guidance Technology appraisal guidance 27 March ...

Our highly specialised technologies (HST) programme is designed specifically to evaluate technologies for ultra-rare, debilitating conditions. It helps encourage research and innovation in areas where ...

While annual physical checks already take place for people with long-term conditions, we've found that BMI and waist-to-height measurements aren't consistently recorded. Our new approach addresses ...

Further information The NICE-Wide Prioritisation Board and NHS England have agreed that a Technology Appraisal (TA) would not be appropriate for this product and recommended that it is not selected ...

Please note that following on from information provided to NICE by the company in February 2024 the appraisal was suspended from NICE’s work programme. As no further information has been received from ...